Analysis 33 patients of non-DS-AMKL with or without acquired trisomy 21 from multiple centers and compared to 118 AML patients

References

• Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937–951. doi:10.1182/blood-2009-03-209262
   PubMed Web of Science ®Google Scholar
• Gruber TA, Downing JR. The biology of pediatric acute megakaryoblastic leukemia. Blood. 2015;126(8):943–949. doi:10.1182/blood-2015-05-567859
   PubMed Web of Science ®Google Scholar
• Athale UH, Razzouk BI, Raimondi SC, et al. Biology and outcome of childhood acute megakaryoblastic leukemia: a single institution’s experience. Blood. 2001;97(12):3727–3732. doi:10.1182/blood.V97.12.3727
   PubMed Web of Science ®Google Scholar
• Garnett C, Cruz Hernandez D, Vyas P. GATA1 and cooperating mutations in myeloid leukaemia of Down syndrome. IUBMB Life. 2020;72(1):119–130. doi:10.1002/iub.2197
   PubMed Web of Science ®Google Scholar
• Roberts I, O’Connor D, Roy A, et al. The impact of trisomy 21 on foetal haematopoiesis. Blood Cells Mol Dis. 2013;51(4):277–281. doi:10.1016/j.bcmd.2013.07.008
   PubMed Web of Science ®Google Scholar
• Wan TS, Au WY, Chan JC, et al. Trisomy 21 as the sole acquired karyotypic abnormality in acute myeloid leukemia and myelodysplastic syndrome. Leuk Res. 1999;23(11):1079–1083. doi:10.1016/S0145-2126(99)00117-4
   PubMed Web of Science ®Google Scholar
• Schweitzer J, Zimmermann M, Rasche M, et al. Improved outcome of pediatric patients with acute megakaryoblastic leukemia in the AML-BFM 04 trial. Ann Hematol. 2015;94(8):1327–1336. doi:10.1007/s00277-015-2383-2
   PubMed Web of Science ®Google Scholar
• Inaba H, Zhou Y, Abla O, et al. Heterogeneous cytogenetic subgroups and outcomes in childhood acute megakaryoblastic leukemia: a retrospective international study. Blood. 2015;126(13):1575–1584. doi:10.1182/blood-2015-02-629204
   PubMed Web of Science ®Google Scholar
• Ono R, Hasegawa D, Hirabayashi S, et al. Acute megakaryoblastic leukemia with acquired trisomy 21 and GATA1 mutations in phenotypically normal children. Eur J Pediatr. 2015;174(4):525–531. doi:10.1007/s00431-014-2430-3
   PubMed Web of Science ®Google Scholar
• Marques-Piubelli ML. Acute megakaryoblastic leukemia with t(1;22)(p13.3;q13.1); RBM15-MKL1 mimicking hepatoblastoma in an infant: The role of karyotype in differential diagnosis. Pediatr Blood Cancer. 2020 Mar;67(3):e28111. doi: 10.1002/pbc.28111.
   PubMed Web of Science ®Google Scholar
• Maarouf N, Mahmoud S, Khedr R, et al. Outcome of childhood acute megakaryoblastic leukemia: Children’s Cancer Hospital Egypt 57357 experience. Clin Lymphoma Myeloma Leuk. 2019;19(3):e142–e152. doi:10.1016/j.clml.2018.12.011
   PubMed Web of Science ®Google Scholar
• Zhao G, Wu W, Wang X, et al. Clinical diagnosis of adult patients with acute megakaryocytic leukemia. Oncol Lett. 2018;16(6):6988–6997. doi: 10.3892/ol.2018.9501
   PubMed Web of Science ®Google Scholar
• Khan I, Malinge S, Crispino J. Myeloid leukemia in Down syndrome. Crit Rev Oncog. 2011;16(1-2):25–36. doi:10.1615/CritRevOncog.v16.i1-2.40
   PubMedGoogle Scholar
• Savasan S, Buck S, Raimondi SC, et al. CD36 (thrombospondin receptor) expression in childhood acute megakaryoblastic leukemia: in vitro drug sensitivity and outcome. Leuk Lymphoma. 2006;47(10):2076–2083. doi:10.1080/10428190600773180
   PubMed Web of Science ®Google Scholar
• McNulty M, Crispino JD. Acute megakaryocytic leukemia. Cold Spring Harb Perspect Med. 2020;10(2):a034884. doi:10.1101/cshperspect.a034884
   PubMed Web of Science ®Google Scholar
• Evans EJ Jr, DeGregori J. Dissecting stepwise mutational impairment of megakaryopoiesis in a model of Down syndrome-associated leukemia. J Clin Invest. 2022;132(14). doi:10.1172/JCI161659
   Web of Science ®Google Scholar
• Huret JL, Léonard C. Chromosome 21 and platelets: a gene dosage effect? Clin Genet. 1997;51(2):140–141. doi:10.1111/j.1399-0004.1997.tb02442.x
   PubMed Web of Science ®Google Scholar
• Hama A, Yagasaki H, Takahashi Y, et al. Acute megakaryoblastic leukaemia (AMKL) in children: a comparison of AMKL with and without Down syndrome. Br J Haematol. 2008;140(5):552–561. doi:10.1111/j.1365-2141.2007.06971.x
   PubMed Web of Science ®Google Scholar
• Lee WY, Weinberg OK, Pinkus GS. GATA1 is a sensitive and specific nuclear marker for erythroid and megakaryocytic lineages. Am J Clin Pathol. 2017;147(4):420–426. doi:10.1093/ajcp/aqx018
   PubMed Web of Science ®Google Scholar
• Crispino JD, Horwitz MS. GATA factor mutations in hematologic disease. Blood. 2017;129(15):2103–2110. doi:10.1182/blood-2016-09-687889
   PubMed Web of Science ®Google Scholar
• Bourquin JP, Subramanian A, Langebrake C, et al. Identification of distinct molecular phenotypes in acute megakaryoblastic leukemia by gene expression profiling. Proc Natl Acad Sci U S A. 2005;103(9):3339–3344. doi:10.1073/pnas.0511150103
   Web of Science ®Google Scholar
• Alejo-Valle O, Weigert K, Bhayadia R, et al. The megakaryocytic transcription factor ARID3A suppresses leukemia pathogenesis. Blood. 2022;139(5):651–665. doi:10.1182/blood.2021012231
   PubMed Web of Science ®Google Scholar
• Lopez CK, Malinge S, Gaudry M, et al. Pediatric acute megakaryoblastic leukemia: multitasking fusion proteins and oncogenic cooperations. Trends Cancer. 2017;3(9):631–642. doi:10.1016/j.trecan.2017.07.003
   PubMed Web of Science ®Google Scholar
• Wang SA, Hasserjian RP. Acute erythroleukemias, acute megakaryoblastic leukemias, and reactive mimics: A guide to a number of perplexing entities. Am J Clin Pathol. 2015;144(1):44–60. doi:10.1309/AJCPRKYAT6EZQHC7
   PubMed Web of Science ®Google Scholar
• Shin M-G, Choi H-W, Kim H-R, et al. Tetrasomy 21 as a sole acquired abnormality without GATA1 gene mutation in pediatric acute megakaryoblastic leukemia: a case report and review of the literature. Leuk Res. 2008;32(10):1615–1619. doi:10.1016/j.leukres.2008.02.010
   PubMed Web of Science ®Google Scholar
• Terui K, Toki T, Taga T, et al. Highly sensitive detection of GATA1 mutations in patients with myeloid leukemia associated with Down syndrome by combining Sanger and targeted next generation sequencing. Genes Chromosomes Cancer. 2020;59(3):160–167. doi:10.1002/gcc.22816
   PubMed Web of Science ®Google Scholar
• Ho PA, Alonzo TA, Gerbing RB, et al. The prognostic effect of high diagnostic WT1 gene expression in pediatric AML depends on WT1 SNP rs16754 status: report from the Children’s Oncology Group. Pediatr Blood Cancer. 2014;61(1):81–88. doi:10.1002/pbc.24700
   PubMed Web of Science ®Google Scholar
• De Braekeleer M, Le Bris MJ, De Braekeleer E, et al. 3q26/EVI1 rearrangements in myeloid hemopathies: a cytogenetic review. Future Oncol. 2015;11(11):1675–1686. doi:10.2217/fon.15.64
   PubMed Web of Science ®Google Scholar
• Jo A, Mitani S, Shiba N, et al. High expression of EVI1 and MEL1 is a compelling poor prognostic marker of pediatric AML. Leukemia. 2015;29(5):1076–1083. doi:10.1038/leu.2015.5
   PubMed Web of Science ®Google Scholar
• Stolzel F, Mohr B, Kramer M, et al. Karyotype complexity and prognosis in acute myeloid leukemia. Blood Cancer J. 2016;6:e386. doi:10.1038/bcj.2015.114
   PubMed Web of Science ®Google Scholar
• Huang J, Hu G, Suo P, et al. Unmanipulated haploidentical hematopoietic stem cell transplantation for pediatric de novo acute megakaryoblastic leukemia without Down syndrome in China: a single-center study. Front Oncol. 2023;13:1116205. doi:10.3389/fonc.2023.1116205
   PubMed Web of Science ®Google Scholar
• Hama A, Taga T, Tomizawa D, et al. Haematopoietic cell transplantation for children with acute megakaryoblastic leukaemia without Down syndrome. Br J Haematol. 2023 May;201(4):747–756. doi: 10.1111/bjh.18691
   PubMed Web of Science ®Google Scholar